using stem cells to treat ocular surface diseases and disorders

11
Using Stem Cells to Treat Ocular Surface Diseases and Disorders C.S. Woodson, E. Meyer-Blazejewska, F.E. Kruse, M.K. Call, W.K. Edith J. Crawley Vision Research Center,

Upload: carol

Post on 24-Feb-2016

26 views

Category:

Documents


0 download

DESCRIPTION

Using Stem Cells to Treat Ocular Surface Diseases and Disorders. C.S. Woodson, E. Meyer- Blazejewska , F.E. Kruse, M.K. Call, W.K. Edith J. Crawley Vision Research Center, University of Cincinnati. Background. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

Using Stem Cells to Treat

Ocular Surface Diseases and

DisordersC.S. Woodson, E. Meyer-Blazejewska, F.E. Kruse, M.K. Call, W.K.Edith J. Crawley Vision Research Center, University of Cincinnati

Page 2: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

BackgroundLimbal epithelial stem cells are located in the limbus, a thin band along the edge of the iris. These cells are responsible for replenishing the cells of the transparent, avascular cornea andseparating them from the opaque, conjunctival tissue of the eye that contains blood vessels. Corneal injury or genetic defects can prevent proper cell barrier and replenishment function or destroy them all together, a disorder called Limbal Stem Cell Deficiency (LSCD). As a result, the conjunctiva grows uncontrollably over the clear cornea and causes blindness.

Page 3: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

Currently, patients with unilateral LSCD are able to transplant healthy limbal stem cells from the healthy eye to the diseased one to treat LSCD. However, patients with bilateral LSCD cannot do this process and if they accept a transplant from a donor, rejection of the donated cells is possible.

To explore the therapeutic potential of bulge-derived hair follicle stem cells to treat LSCD.

Purpose

Page 4: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

In this study, we addressed the hypothesis that when transplanted, Hair Follicle Stem Cells (HFSCs) will develop into the corneal epithelial cells needed to treat LSCD.

Hypothesis

Tri-transgenic mice (K12rtTA /tetO-Cre/RosamTmG) were utilized to harvest HFSCs. Wild-type mice were then given LSCD by the complete removal of all epithelium with a corneal rust-ring remover. The isolated HFSCs were transplanted on a fibrin carrier onto wild-type LSCD mice. Factors in the corneal environment signaled HFSCs to differentiate into corneal cells, exhibited by expression of K12 (in green).

Method

Page 5: Using Stem Cells to Treat Ocular Surface Diseases and Disorders
Page 6: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

I. Hair Follicle Stem Cell (HFSC) IsolationMurine HFSCs were isolated, in order to access the bulge region harboring the epithelial stem cells, which express keratin 15 (Krt15) in green.

Page 7: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

ResultsI. HFSC transplantThe HFCS from K12rtTA /tetO-Cre/RosamTmG mouse were placed on a wild-type C57/Black6 mouse with induced LSCD (A) and sutured on (B). The eye was then examined post-transplantation under red light (C) and green light (D).

Page 8: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

II. Keratin12 (K12) production post-transplantKeratin 12, considered a molecular marker of corneal epithelial cells, is detected with EGFP within 3 days (A) and 2 weeks (B) post-transplantation.

Page 9: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

III. HFSC in actionHFSCs replaced nonfunctional limbal stem cells and began barrier function and replenishment of avascular cornea once more.

A-H are 4 weeks after epithelial tissue was removed (induced LSCD). A-D are images from an LSCD mouse that received a transplants. Images E-H are a control LSCD mouse.

Page 10: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

ConclusionHFSCs can differentiate into corneal epithelial cells.HFSCs have therapeutic potential for LSCD patients with an 80%

success rate.

Next StepsNow, we have begun examining environmental factors that cue maintenance and differentiation of limbal stem cells. PPARɣ, a transcription factor, is thought to be one of these factors. This is evident in the human limbus and cornea where PPARɣ density is high in limbus and decreases as you move towards central cornea (A). In mice, PPARɣ is expressed in limbus (B) and only weakly in the central cornea.

Page 11: Using Stem Cells to Treat Ocular Surface Diseases and Disorders

(A)

Human corneal epithelium

Human limbus Mouse limbus

(B)

Mouse corneal epithelium